BAUSCH Health

News Releases

Register for email alerts.

All Categories

Archive

Date 12/23/11

Title

Valeant Pharmaceuticals Completes Syndication of Incremental Term Loans

Download PDF

Date 12/22/11

Title

Valeant Pharmaceuticals to Hold Conference Call to Announce 2012 Financial Guidance

Download PDF

Date 12/22/11

Title

Valeant Pharmaceuticals Completes Acquisition of iNova

Download PDF

Date 12/19/11

Title

Valeant Pharmaceuticals Completes Acquisition of Dermik

Download PDF

Date 12/16/11

Title

Valeant Pharmaceuticals Proposes to Acquire ISTA Pharmaceuticals Inc. for $6.50 Per Share in Cash

Download PDF

Date 12/16/11

Title

Valeant Announces Successful Results From Phase III Onychomycosis Trials

Download PDF

Date 12/12/11

Title

Valeant Announces the Completion of the Privatization of Afexa Life Sciences Inc.

Download PDF

Date 12/12/11

Title

Valeant Pharmaceuticals Receives Approval From FTC in Connection With Acquisition of Ortho Dermatologics and Dermik

Download PDF

Date 11/30/11

Title

Valeant Pharmaceuticals to Syndicate Incremental Term Loans

Download PDF

Date 11/20/11

Title

Valeant Pharmaceuticals Agrees to Acquire iNova

Download PDF

Date 11/10/11

Title

Valeant Pharmaceuticals Appoints Howard B. Schiller as Chief Financial Officer

Download PDF

Date 11/03/11

Title

Valeant Pharmaceuticals Reports 2011 Third Quarter Financial Results

Download PDF

Date 11/03/11

Title

Valeant Announces New $1.5 Billion Securities Repurchase Program

Download PDF

Date 10/27/11

Title

Valeant Announces Take-Up of Additional Afexa Shares and Special Meeting of Shareholders of Afexa to Approve Its Privatization

Download PDF

Date 10/21/11

Title

Valeant Pharmaceuticals Successfully Completes Refinancing of Senior Secured Credit Facilities

Download PDF

Date 10/21/11

Title

Valeant Pharmaceuticals to Announce 2011 Third Quarter Results on November 3, 2011

Download PDF

Date 10/18/11

Title

Valeant Announces Results of Friendly Offer for Afexa Life Sciences Inc.

Download PDF

Date 09/30/11

Title

Valeant Announces That Afexa Supports and Recommends Valeant's Increased Offer and Agrees to Certain Amendments to Support Agreement

Download PDF

Date 09/28/11

Title

Valeant Pharmaceuticals Announces Approval Of Colesevelam Hydrochloride In Canada

Download PDF

Date 09/26/11

Title

Valeant Pharmaceuticals Intends to Raise Offer for Afexa Life Sciences Inc. to $0.85 per Share

Download PDF

Date 09/26/11

Title

Valeant Pharmaceuticals to Refinance Senior Secured Credit Facilities

Download PDF

Date 09/20/11

Title

Valeant Pharmaceuticals Announces Second Request from the Federal Trade Commission in Connection with Pending Dermatology Acquisitions

Download PDF

Date 09/09/11

Title

Valeant Pharmaceuticals Announces Mailing of Offer and Take-Over Bid Circular to Shareholders of Afexa

Download PDF

Date 09/02/11

Title

Valeant Pharmaceuticals to Present at Industry Conferences

Download PDF

Date 08/30/11

Title

Valeant Pharmaceuticals Announces All-Cash Offer to Acquire Afexa Life Sciences Inc.

Download PDF

Date 08/29/11

Title

Valeant Pharmaceuticals Announces Increase to Monetary Limit Under Its Securities Repurchase Program

Download PDF

Date 08/23/11

Title

Valeant Pharmaceuticals Files a Notice of Intention to Make a Normal Course Issuer Bid

Download PDF

Date 08/19/11

Title

Valeant Pharmaceuticals Completes Acquisition of Sanitas Group

Download PDF

Date 08/18/11

Title

Valeant Pharmaceuticals Announces Resignation of Michael Van Every From Valeant's Board of Directors

Download PDF

Date 08/04/11

Title

Valeant Pharmaceuticals Reports 2011 Second Quarter Financial Results

Download PDF

Date 08/03/11

Title

Valeant Pharmaceuticals Appoints Ronald Farmer to Fill Board Vacancy

Download PDF

Date 08/03/11

Title

Valeant Pharmaceuticals International, Inc.

Download PDF

Date 07/25/11

Title

Valeant Pharmaceuticals Announces Approval of Sublinox® in Canada

Download PDF

Date 07/20/11

Title

Valeant Pharmaceuticals to Announce 2011 Second Quarter Results on August 4, 2011

Download PDF

Date 07/19/11

Title

Valeant Pharmaceuticals Announces Distribution Agreement for Zuacta(TM) in Canada

Download PDF

Date 07/15/11

Title

Valeant Pharmaceuticals Agrees to Acquire Ortho Dermatologics

Download PDF

Date 07/11/11

Title

Valeant Pharmaceuticals Agrees to Acquire Dermik

Download PDF

Date 06/30/11

Title

Valeant Pharmaceuticals Announces License Agreement With Meda for North American Rights for Elidel® and Xerese(TM)

Download PDF

Date 06/13/11

Title

Valeant and GlaxoSmithKline Announce U.S. FDA Approval of Potiga(TM) (ezogabine)

Download PDF

Date 05/24/11

Title

Valeant Pharmaceuticals Agrees to Acquire Sanitas Group for Approximately EUR314 Million in Cash

Download PDF

Date 05/16/11

Title

Kinerase® Introduces "Change Your Skin, Change Your Life" Charity Campaign

Download PDF

Date 05/11/11

Title

Valeant Pharmaceuticals to Webcast 2011 Annual Meeting of Shareholders

Download PDF

Date 05/09/11

Title

Valeant Pharmaceuticals Reports 2011 First Quarter Financial Results

Download PDF

Date 05/02/11

Title

Valeant Pharmaceuticals Congratulates Teva and Cephalon on Their Transaction

Download PDF

Date 04/29/11

Title

Valeant Pharmaceuticals to Announce 2011 First Quarter Results on May 9, 2011

Download PDF

Date 04/21/11

Title

Valeant Pharmaceuticals Announces Letter to Cephalon Stockholders

Download PDF

Date 04/21/11

Title

Valeant Pharmaceuticals Responds to Cephalon Board's Letter

Download PDF

Date 04/20/11

Title

Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013

Download PDF

Date 04/18/11

Title

Regulatory Update - GSK and Valeant Respond to FDA on ezogabine

Download PDF

Date 04/18/11

Title

Valeant Pharmaceuticals Adds Corporate Governance Expert Abe Friedman to its Slate of Proposed Cephalon Directors

Download PDF

Date 04/11/11

Title

Valeant Pharmaceuticals Files Presentation for Cephalon Stockholders

Download PDF

Date 04/07/11

Title

Meda to License Elidel to Valeant Pharmaceuticals

Download PDF

Date 04/05/11

Title

Valeant Pharmaceuticals Files Preliminary Consent Solicitation Statement With the SEC

Download PDF

Date 04/01/11

Title

Promius Pharma and Valeant Form Collaboration to Market Cloderm(R) Cream in the United States

Download PDF

Date 03/29/11

Title

Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash

Download PDF

Date 03/29/11

Title

GSK and Valeant Receive European Authorisation for Trobalt (retigabine)

Download PDF

Date 03/22/11

Title

Valeant Pharmaceuticals Extends Contract with J. Michael Pearson as CEO and Appoints Him as Chairman of the Board

Download PDF

Date 03/11/11

Title

Valeant Pharmaceuticals Completes Acquisition of PharmaSwiss S.A.

Download PDF

Date 03/03/11

Title

Valeant Announces Pricing of Senior Notes

Download PDF

Date 03/01/11

Title

Valeant Launches Senior Notes Offering

Download PDF

Date 02/24/11

Title

Valeant Pharmaceuticals Reports 2010 Fourth Quarter Financial Results

Download PDF

Date 02/16/11

Title

Valeant Pharmaceuticals to Present at RBC Capital Markets' 2011 Healthcare Conference

Download PDF

Date 02/15/11

Title

Valeant Pharmaceuticals to Announce 2010 Fourth Quarter and Full Year Results on February 24, 2011

Download PDF

Date 02/10/11

Title

Valeant Pharmaceuticals Announces Acquisition of Cholestagel(R) in Canada

Download PDF

Date 02/08/11

Title

Valeant Pharmaceuticals Announces License Of ACZONE(R) (dapsone) Gel 5% In Canada

Download PDF

Date 02/03/11

Title

Valeant Launches Senior Notes Offering

Download PDF

Date 02/03/11

Title

Valeant Announces Pricing of Senior Notes

Download PDF

Date 02/03/11

Title

Valeant Pharmaceuticals to Acquire U.S. and Canadian Rights to Zovirax(R)

Download PDF

Date 02/01/11

Title

Valeant Pharmaceuticals to Acquire PharmaSwiss S.A.

Download PDF

Date 01/21/11

Title

Regulatory Update - GSK and Valeant Receive Positive Opinion in Europe From the CHMP for Trobalt (Retigabine)

Download PDF

Date 01/10/11

Title

Valeant Pharmaceuticals to Present at J.P. Morgan 29th Annual Health Care Conference

Download PDF

Investor Inquiries
ir@bauschhealth.com
877-281-6642
514-856-3855 (Canada)

Media inquiries
Corporate.communications@bauschhealth.com
848-264-0934

LEGAL NOTICE PRIVACY POLICY

EMAIL ALERTS EMAIL PAGE RSS FEED

Use of this site signifies your agreement to the Legal Notice and Privacy Policy.
©2026 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION

Powered by SITECORE